Title : Development of De Novo Donor-specific HLA Antibodies and AMR in Renal Transplant Patients Depends on CYP3A5 Genotype.

Pub. Date : 2022 May 1

PMID : 34241984






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Persons carrying at least one copy of the wild-type allele, defined as CYP3A5 expressers, exhibit higher clearance and lower trough concentrations of tacrolimus than homozygous nonexpressers, and this difference may affect alloimmunization and allograft function. Tacrolimus cytochrome P450 family 3 subfamily A member 5 Homo sapiens
2 During the first 3 years after transplant, CYP3A5 expressers tended to have lower tacrolimus trough levels than non-expressers, even though their tacrolimus dosage was as much as 80% higher. Tacrolimus cytochrome P450 family 3 subfamily A member 5 Homo sapiens
3 CONCLUSIONS: Early detection of CYP3A5 expressers, enabling genotype-based dose adjustment of tacrolimus immediately after renal transplant, may be a useful strategy for reducing the risk of de novo DSA production and antibody-mediated rejection. Tacrolimus cytochrome P450 family 3 subfamily A member 5 Homo sapiens